You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
远大医药(00512.HK)中期纯利增长73.4%至5.47亿港元
格隆汇 08-13 20:32

格隆汇8月13日丨远大医药(00512.HK)公布中期业绩,截至2019年6月30日止6个月,公司实现收益35.87亿港元,同比增长10.85%;毛利22.72亿港元,同比增长21.7%;公司拥有人应占盈利5.47亿港元,同比增长73.4%;基本每股盈利17.22港仙 ;不派中期股息。

公告表示,报告期内,集团收益增长的主要原因包括本集团大力发展具有市场和技术壁垒的特色医药产品、独家或受保护医药产品以及品牌药产品等,特别是医药制剂板块录得明显的增长。而且通过持续调整产品结构,高毛利产品占比得到不断提升,致使集团于期内的平均毛利率提高至约 63.4%,较2018年同期的约57.7%大幅提高了约5.7个百分点。

期内公司拥有人应占期内盈利约为5.47亿港元,除了受惠于收入及毛利增加外,应占联营公司盈利净额亦录得约1243万港元,因此于2019年上半年集团拥有人应占期内盈利较2018年同期增长约73.4%。如果撇除人民币贬值影响,与去年期比较集团收益增长约18.1%,集团拥有人应占期内盈利增长约86.8%。

公司表示,集团经过多年的积累和发展,尤其是最近五年以来,已经在心脑血管疾病、癌症和呼吸系统疾病三个领域,奠定了良好的基础。无论是产品品种数量、核心市场占有率、市场学术推广和核心意见领袖(KOL)网路建设、产品商业化能力、国际化专业研究能力人才储备,以及未来药物及医疗器械重磅产品的储备等等方面,集团都在积极准备,迎接产业发展与突破的机会。

集团在心脑血管专科产品领域,尤其是急救药物方面,市场占有率高,销售收入持续稳健增长。国家急抢救药品目录涵盖八大类药品,四十八个品种,公司的核心产品已涉及其中的六大类、十一个品种。在细分领域中,心脏兴奋药物的品类最多,是市场的领导者之一。目前部分核心产品已被筛选纳入国家短缺急救药品储备目录中,将会受到国家有关供应保障政策的保护。在未来产品的储备方面,集团除了自主研发的临床急需首仿药物之外,还会陆续将具有国际性创新性的介入治疗器械和诊断装置类重磅产品在中国落地注册,待陆续上市后,为广大医患提供更多更新的治疗产品。

此外,中国医药市场会跟随国际其他发达国家的发展路径,不断前行。可是,因为医药行业创新理念和人才储备不足,政府介入深而具体,所以市场走向成熟可能需要更多的周折和时间。以服务患者为中心,以市场需求为导向,以研发为基础,是集团未来发展的核心理念,是集团从壁垒品牌产品转型到创新优势产品的发展路径。集团将充分发挥自己的综合发展优势,拓展全球市场,提高市场覆盖及国际化发展能力,坚持自主研发、专利授权和协同性投资并购的整合型发展战略,信守法规和阳光法案经营,履行社会责任,为病患、员工和股东带来持续均衡的利益回报,成为受医生和患者尊重医药企业,成为中国医药市场的领导性企企业之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account